New aspects of lipotoxicity in nonalcoholic steatohepatitis

International Journal of Molecular Sciences

Volumn 19, Issue 7, 2018, Pages

  Mendez Sanchez, Nahum ^a   Cruz Ramon, Vania Cesar ^a   Ramirez Perez, Oscar Lenin ^a   Hwang, Jessica P ^b   Barranco Fragoso, Beatriz ^c   Cordova Gallardo, Jaqueline ^d  

^a LIVER RESEARCH UNIT   (Mexico)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c Department of Gastroenterology National Medical Center 20 Noviembre   (Mexico)

^d HOSPITAL GENERAL DR MANUEL GEA GONZÁLEZ   (Mexico)

Author keywords

Hepatic lipotoxicity; Liver fibrosis; Nonalcoholic steatohepatitis

Indexed keywords

ACYL COENZYME A; ADIPOCYTOKINE; ALPHA TOCOPHEROL; BILE ACID; CERAMIDE; CHEMOKINE; FATTY ACID; LIPOPOLYSACCHARIDE; LYSOPHOSPHATIDYLCHOLINE; PATHOGEN ASSOCIATED MOLECULAR PATTERN; PIOGLITAZONE; REACTIVE OXYGEN METABOLITE; SATURATED FATTY ACID; SOMATOMEDIN; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR;

ADIPOCYTE; ADIPOSE TISSUE; BARIATRIC SURGERY; CELL STRESS; COFFEE; DISEASE EXACERBATION; DYSBIOSIS; GASTROINTESTINAL DISEASE; HUMAN; INFLAMMATION; INSULIN RESISTANCE; INTESTINE FLORA; KUPFFER CELL; LIFESTYLE MODIFICATION; LIPOTOXICITY; LIVER CELL CARCINOMA; LIVER FIBROSIS; MACROPHAGE; NEUTROPHIL; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; OXIDATIVE STRESS; PREVALENCE; REVIEW; SILYBUM MARIANUM; BIOLOGICAL MODEL; LIVER; LIVER CIRRHOSIS; METABOLISM; PATHOLOGY;

ADIPOKINES; ADIPOSE TISSUE; DISEASE PROGRESSION; FATTY ACIDS; HUMANS; INSULIN RESISTANCE; LIVER; LIVER CIRRHOSIS; MODELS, BIOLOGICAL; NON-ALCOHOLIC FATTY LIVER DISEASE;

EID: 85050164141     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms19072034     Document Type: Review

References (161)

1. Almeda-Valdes, P.; Aguilar-Olivos, N.; Uribe, M.; Méndez-Sánchez, N. Common features of the metabolic syndrome and nonalcoholic fatty liver disease. Rev. Recent Clin. Trials 2014, 3, 148–158. [CrossRef]
2. Benedict, M.; Zhang, X. Non-alcoholic fatty liver disease: An expanded review. World J. Hepatol. 2017, 16, 715–732. [CrossRef] [PubMed]
3. Brunt, E.M. Nonalcoholic steatohepatitis: Definition and pathology. Semin. Liver Dis. 2001, 1, 3–16. [CrossRef]
4. Chiang, J.Y.L. Targeting bile acids and lipotoxicity for NASH treatment. Hepatol. Commun. 2017, 10, 1002–1004. [CrossRef] [PubMed]
5. Browning, J.D.; Horton, J.D. Molecular mediators of hepatic steatosis and liver injury. J. Clin. Investig. 2004, 2, 147–152. [CrossRef]
6. Caligiuri, A.; Gentilini, A.; Marra, F. Molecular pathogenesis of NASH. Int. J. Mol. Sci. 2016, 17, E1575. [CrossRef] [PubMed]
7. Engin, A.B. What Is Lipotoxicity? Adv. Exp. Med. Biol. 2017, 960, 197–220. [CrossRef] [PubMed]
8. Trauner, M.; Arrese, M.; Wagner, M. Fatty liver and lipotoxicity. Biochim. Biophys. Acta 2010, 1801, 299–310. [CrossRef] [PubMed]
9. Alkhouri, N.; Dixon, L.J.; Feldstein, A.E. Lipotoxicity in nonalcoholic fatty liver disease: Not all lipids are created equal. Expert Rev. Gastroenterol. Hepatol. 2009, 3, 445–451. [CrossRef] [PubMed]
10. Shen, W.; Wang, Z.; Punyanita, M.; Lei, J.; Sinav, A.; Kral, J.G.; Imielinska, C.; Ross, R.; Heymsfield, S.B. Adipose tissue quantification by imaging methods: A proposed classification. Obes. Res. 2003, 11, 5–16. [CrossRef] [PubMed]
11. Heinemann, A.; Wischhusen, F.; Püschel, K.; Rogiers, X. Standard liver volume in the Caucasian population. Liver Transplant. Surg. 1999, 5, 366–368. [CrossRef] [PubMed]
12. Hübers, M.; Geisler, C.; Bosy-Westphal, A.; Braun, W.; Pourhassan, M.; Sørensen, T.I.A.; Müller, M.J. Association between fat mass, adipose tissue, fat fraction per adipose tissue, and metabolic risks: A cross-sectional study in normal, overweight, and obese adults. Eur. J. Clin. Nutr. 2018. [CrossRef] [PubMed]
13. Neamat-Allah, J.; Wald, D.; Hüsing, A.; Teucher, B.; Wendt, A.; Delorme, S.; Dinkel, J.; Vigl, M.; Bergmann, M.M.; Feller, S.; et al. Validation of anthropometric indices of adiposity against whole-body magnetic resonance imaging—A study within the German European Prospective Investigation into Cancer and Nutrition (EPIC) cohorts. PLoS ONE 2014, 9, e91586. [CrossRef] [PubMed]
14. Lombardo, G.E.; Lepore, S.M.; Morittu, V.M.; Arcidiacono, B.; Colica, C.; Procopio, A.; Maggisano, V.; Bulotta, S.; Costa, N.; Mignogna, C.; et al. Effects of oleacein on high-fat diet-dependent steatosis, weight gain, and insulin resistance in mice. Front. Endocrinol. (Lausanne) 2018, 9, 116. [CrossRef] [PubMed]
15. Parekh, S.; Anania, F.A. Abnormal lipid and glucose metabolism in obesity: Implications for nonalcoholic fatty liver disease. Gastroenterology 2007, 132, 2191–2207. [CrossRef] [PubMed]
16. Fox, C.S.; Massaro, J.M.; Hoffmann, U.; Pou, K.M.; Maurovich-Horvat, P.; Liu, C.Y.; Vasan, R.S.; Murabito, J.M.; Meigs, J.B.; Cupples, L.A.; et al. Abdominal visceral and subcutaneous adipose tissue compartments: Association with metabolic risk factors in the Framingham Heart Study. Circulation 2007, 116, 39–48. [CrossRef] [PubMed]
17. Roberts, E.A. Pediatric nonalcoholic fatty liver disease (NAFLD): A growing problem? J. Hepatol. 2007, 46, 1133–1142. [CrossRef] [PubMed]
18. Festi, D.; Colecchia, A.; Sacco, T.; Bondi, M.; Roda, E.; Marchesini, G. Hepatic steatosis in obese patients: Clinical aspects and prognostic significance. Obes. Rev. 2004, 5, 27–42. [CrossRef] [PubMed]
19. Shoelson, S.E.; Herrero, L.; Naaz, A. Obesity, inflammation, and insulin resistance. Gastroenterology 2007, 132, 2169–2180. [CrossRef] [PubMed]
20. Lenz, A.; Diamond, F.B., Jr. Obesity: The hormonal milieu. Curr. Opin. Endocrinol. Diabetes Obes. 2008, 15, 9–20. [CrossRef] [PubMed]
21. Ramírez-Pérez, O.; Cruz-Ramón, V.; Chinchilla-López, P.; Méndez-Sánchez, N. The role of the gut microbiota in bile acid metabolism. Ann. Hepatol. 2017, 16 (Suppl. 1), s15–s20. [CrossRef] [PubMed]
22. Compare, D.; Coccoli, P.; Rocco, A.; Nardone, O.M.; De Maria, S.; Cartenì, M.; Nardone, G. Gut liver axis: The impact of gut microbiota on nonalcoholic fatty liver disease. Nutr. Metab. Cardiovasc. Dis. 2012, 22, 471–476. [CrossRef] [PubMed]
23. Trujillo, M.E.; Scherer, P.E. Adipose tissue-derived factors: Impact on health and disease. Endocr. Rev. 2006, 27, 762–778. [CrossRef] [PubMed]
24. Bunnell, B.A.; Flaat, M.; Gagliardi, C.; Patel, B.; Ripoll, C. Adipose-derived stem cells: Isolation, expansion and differentiation. Methods 2008, 45, 115–120. [CrossRef] [PubMed]
25. Alkhouli, N.; Mansfield, J.; Green, E.; Bell, J.; Knight, B.; Liversedge, N.; Tham, J.C.; Welbourn, R.; Shore, A.C.; Kos, K.; et al. The mechanical properties of human adipose tissues and their relationships to the structure and composition of the extracellular matrix. Am. J. Physiol. Endocrinol. Metab. 2013, 305, E1427–E1435. [CrossRef] [PubMed]
26. Gray, S.L.; Vidal-Puig, A.J. Adipose tissue expandability in the maintenance of metabolic homeostasis. Nutr. Rev. 2007, 65 Pt 2, S7–S12. [CrossRef] [PubMed]
27. Cusi, K. Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: Pathophysiology and clinical implications. Gastroenterology 2012, 142, 711–725. [CrossRef] [PubMed]
28. Mota, M.; Banini, B.A.; Cazanave, S.C.; Sanyal, A.J. Molecular mechanisms of lipotoxicity and glucotoxicity in nonalcoholic fatty liver disease. Metabolism 2016, 65, 1049–1061. [CrossRef] [PubMed]
29. Saponaro, C.; Gaggini, M.; Carli, F.; Gastaldelli, A. The subtle balance between lipolysis and lipogenesis: A critical point in metabolic homeostasis. Nutrients 2015, 7, 9453–9474. [CrossRef] [PubMed]
30. Duncan, R.E.; Ahmadian, M.; Jaworski, K.; Sarkadi-Nagy, E.; Sul, H.S. Regulation of lipolysis in adipocytes. Annu. Rev. Nutr. 2007, 27, 79–101. [CrossRef] [PubMed]
31. Ahmadian, M.; Duncan, R.E.; Jaworski, K.; Sarkadi-Nagy, E.; Sul, H.S. Triacylglycerol metabolism in adipose tissue. Future Lipidol. 2007, 2, 229–237. [CrossRef] [PubMed]
32. Czech, M.P.; Tencerova, M.; Pedersen, D.J.; Aouadi, M. Insulin signalling mechanisms for triacylglycerol storage. Diabetologia 2013, 56, 949–964. [CrossRef] [PubMed]
33. Claus, T.H.; Lowe, D.B.; Liang, Y.; Salhanick, A.I.; Lubeski, C.K.; Yang, L.; Lemoine, L.; Zhu, J.; Clairmont, K.B. Specific inhibition of hormone-sensitive lipase improves lipid profile while reducing plasma glucose. J. Pharmacol. Exp. Ther. 2005, 315, 1396–1402. [CrossRef] [PubMed]
34. Laforenza, U.; Scaffino, M.F.; Gastaldi, G. Aquaporin-10 represents an alternative pathway for glycerol efflux from human adipocytes. PLoS ONE 2013, 8, e54474. [CrossRef] [PubMed]
35. Calderon-Dominguez, M.; Mir, J.F.; Fucho, R.; Weber, M.; Serra, D.; Herrero, L. Fatty acid metabolism and the basis of brown adipose tissue function. Adipocyte 2016, 5, 98–118. [CrossRef] [PubMed]
36. Brumbaugh, D.E.; Friedman, J.E. Developmental origins of nonalcoholic fatty liver disease. Pediatr. Res. 2014, 75, 140–147. [CrossRef] [PubMed]
37. Di Pasquale, M.G. The essentials of essential fatty acids. J. Diet. Suppl. 2009, 6, 143–161. [CrossRef] [PubMed]
38. Chabowski, A.; Żendzian-Piotrowska, M.; Konstantynowicz, K.; Pankiewicz, W.; Mikłosz, A.; Łukaszuk, B.; Górski, J. Fatty acid transporters involved in the palmitate and oleate induced insulin resistance in primary rat hepatocytes. Acta Physiol. (Oxf.) 2013, 207, 346–357. [CrossRef] [PubMed]
39. Pan, X.; Wang, P.; Luo, J.; Wang, Z.; Song, Y.; Ye, J.; Hou, X. Adipogenic changes of hepatocytes in a high-fat diet-induced fatty liver mice model and non-alcoholic fatty liver disease patients. Endocrine 2015, 48, 834–847. [CrossRef] [PubMed]
40. Boden, G. Obesity and free fatty acids. Endocrinol. Metab. Clin. N. Am. 2008, 37, 635–646. [CrossRef] [PubMed]
41. Donnelly, K.L.; Smith, C.I.; Schwarzenberg, S.J.; Jessurun, J.; Boldt, M.D.; Parks, E.J. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J. Clin. Investig. 2005, 115, 1343–1351. [CrossRef] [PubMed]
42. Stremmel, W.; Staffer, S.; Wannhoff, A.; Pathil, A.; Chamulitrat, W. Plasma membrane phospholipase A2 controls hepatocellular fatty acid uptake and is responsive to pharmacological modulation: Implications for nonalcoholic steatohepatitis. FASEB J. 2014, 28, 3159–3170. [CrossRef] [PubMed]
43. Lewis, G.F.; Carpentier, A.; Adeli, K.; Giacca, A. Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes. Endocr. Rev. 2002, 23, 201–229. [CrossRef] [PubMed]
44. Cambri, L.T.; Ghezzi, A.C.; Arsa, G.; Botezelli, J.D.; de Mello, M.A. Standard short-term diet ameliorates the lipid profile altered by a fructose-rich diet in rats. J. Dev. Orig. Health Dis. 2015, 6, 335–341. [CrossRef] [PubMed]
45. Yamaguchi, K.; Yang, L.; McCall, S.; Huang, J.; Yu, X.X.; Pandey, S.K.; Bhanot, S.; Monia, B.P.; Li, Y.X.; Diehl, A.M. Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis. Hepatology 2007, 45, 1366–1374. [CrossRef] [PubMed]
46. Lauber, K.; Bohn, E.; Kröber, S.M.; Xiao, Y.J.; Blumenthal, S.G.; Lindemann, R.K.; Marini, P.; Wiedig, C.; Zobywalski, A.; Baksh, S.; et al. Apoptotic cells induce migration of phagocytes via caspase-3-mediated release of a lipid attraction signal. Cell 2003, 113, 717–730. [CrossRef]
47. Han, M.S.; Park, S.Y.; Shinzawa, K.; Kim, S.; Chung, K.W.; Lee, J.H.; Kwon, C.H.; Lee, K.W.; Lee, J.H.; Park, C.K.; et al. Lysophosphatidylcholine as a death effector in the lipoapoptosis of hepatocytes. J. Lipid Res. 2008, 49, 84–97. [CrossRef] [PubMed]
48. Yaligar, J.; Gopalan, V.; Kiat, O.W.; Sugii, S.; Shui, G.; Lam, B.D.; Henry, C.J.; Wenk, M.R.; Tai, E.S.; Velan, S.S. Evaluation of dietary effects on hepatic lipids in high fat and placebo diet fed rats by in vivo MRS and LC–MS techniques. PLoS ONE 2014, 9, e91436. [CrossRef] [PubMed]
49. Pathil, A.; Mueller, J.; Warth, A.; Chamulitrat, W.; Stremmel, W. Ursodeoxycholyl lysophosphatidylethanolamide improves steatosis and inflammation in murine models of nonalcoholic fatty liver disease. Hepatology 2012, 55, 1369–1378. [CrossRef] [PubMed]
50. Kakisaka, K.; Cazanave, S.C.; Fingas, C.D.; Guicciardi, M.E.; Bronk, S.F.; Werneburg, N.W.; Mott, J.L.; Gores, G.J. Mechanisms of lysophosphatidylcholine-induced hepatocyte lipoapoptosis. Am. J. Physiol. Gastrointest. Liver Physiol. 2012, 302, G77–G84. [CrossRef] [PubMed]
51. Chavez, J.A.; Siddique, M.M.; Wang, S.T.; Ching, J.; Shayman, J.A.; Summers, S.A. Ceramides and glucosylceramides are independent antagonists of insulin signaling. J. Biol. Chem. 2014, 289, 723–734. [CrossRef] [PubMed]
52. Anjani, K.; L’homme, M.; Sokolovska, N.; Poitou, C.; Aron-Wisnewsky, J.; Bouillot, J.L.; Lesnik, P.; Bedossa, P.; Kontush, A.; Clement, K.; et al. Circulating phospholipid profiling identifies portal contribution to NASH signature in obesity. J. Hepatol. 2015, 62, 905–912. [CrossRef] [PubMed]
53. Schwabe, R.F.; Brenner, D.A. Mechanisms of Liver Injury. I. TNF-alpha-induced liver injury: Role of IKK, JNK, and ROS pathways. Am. J. Physiol. Gastrointest. Liver Physiol. 2006, 290, G583–G589. [CrossRef] [PubMed]
54. Konstantynowicz-Nowicka, K.; Harasim, E.; Baranowski, M.; Chabowski, A. New evidence for the role of ceramide in the development of hepatic insulin resistance. PLoS ONE 2015, 10, e0116858. [CrossRef] [PubMed]
55. Pagadala, M.; Kasumov, T.; McCullough, A.J.; Zein, N.N.; Kirwan, J.P. Role of ceramides in nonalcoholic fatty liver disease. Trends Endocrinol. Metab. 2012, 23, 365–371. [CrossRef] [PubMed]
56. Kasumov, T.; Li, L.; Li, M.; Gulshan, K.; Kirwan, J.P.; Liu, X.; Previs, S.; Willard, B.; Smith, J.D.; McCullough, A. Ceramide as a mediator of non-alcoholic Fatty liver disease and associated atherosclerosis. PLoS ONE 2015, 10, e0126910. [CrossRef] [PubMed]
57. Arguello, G.; Balboa, E.; Arrese, M.; Zanlungo, S. Recent insights on the role of cholesterol in non-alcoholic fatty liver disease. Biochim. Biophys. Acta 2015, 1852, 1765–1778. [CrossRef] [PubMed]
58. Caballero, F.; Fernández, A.; De Lacy, A.M.; Fernández-Checa, J.C.; Caballería, J.; García-Ruiz, C. Enhanced free cholesterol, SREBP-2 and StAR expression in human NASH. J. Hepatol. 2009, 50, 789–796. [CrossRef] [PubMed]
59. Bellanti, F.; Mitarotonda, D.; Tamborra, R.; Blonda, M.; Iannelli, G.; Petrella, A.; Sanginario, V.; Iuliano, L.; Vendemiale, G.; Serviddio, G. Oxysterols induce mitochondrial impairment and hepatocellular toxicity in non-alcoholic fatty liver disease. Free Radic. Biol. Med. 2014, 75 (Suppl. 1), S16–S17. [CrossRef] [PubMed]
60. Gan, L.T.; Van Rooyen, D.M.; Koina, M.E.; McCuskey, R.S.; Teoh, N.C.; Farrell, G.C. Hepatocyte free cholesterol lipotoxicity results from JNK1-mediated mitochondrial injury and is HMGB1 and TLR4-dependent. J. Hepatol. 2014, 61, 1376–1384. [CrossRef] [PubMed]
61. Ferreira, D.M.; Afonso, M.B.; Rodrigues, P.M.; Simão, A.L.; Pereira, D.M.; Borralho, P.M.; Rodrigues, C.M.; Castro, R.E. c-Jun N-terminal kinase 1/c-Jun activation of the p53/microRNA 34a/sirtuin 1 pathway contributes to apoptosis induced by deoxycholic acid in rat liver. Mol. Cell. Biol. 2014, 34, 1100–1120. [CrossRef] [PubMed]
62. Ali, A.H.; Carey, E.J.; Lindor, K.D. Recent advances in the development of farnesoid X receptor agonists. Ann. Transl. Med. 2015, 3, 5. [CrossRef] [PubMed]
63. Khosravi-Far, R.; Esposti, M.D. Death receptor signals to mitochondria. Cancer Biol. Ther. 2004, 3, 1051–1057. [CrossRef] [PubMed]
64. Polimeni, L.; Del Ben, M.; Baratta, F.; Perri, L.; Albanese, F.; Pastori, D.; Violi, F.; Angelico, F. Oxidative stress: New insights on the association of non-alcoholic fatty liver disease and atherosclerosis. World J Hepatol. 2015, 7, 1325–1336. [CrossRef] [PubMed]
65. Tangvarasittichai, S. Oxidative stress, insulin resistance, dyslipidemia and type 2 diabetes mellitus. World J. Diabetes 2015, 6, 456–480. [CrossRef] [PubMed]
66. Rains, J.L.; Jain, S.K. Oxidative stress, insulin signaling, and diabetes. Free Radic. Biol. Med. 2011, 50, 567–575. [CrossRef] [PubMed]
67. Singh, R. Autophagy and regulation of lipid metabolism. Results Probl. Cell Differ. 2010, 52, 35–46. [CrossRef] [PubMed]
68. Mantzaris, M.D.; Tsianos, E.V.; Galaris, D. Interruption of triacylglycerol synthesis in the endoplasmic reticulum is the initiating event for saturated fatty acid-induced lipotoxicity in liver cells. FEBS J. 2011, 278, 519–530. [CrossRef] [PubMed]
69. Hardwick, R.N.; Fisher, C.D.; Canet, M.J.; Lake, A.D.; Cherrington, N.J. Diversity in antioxidant response enzymes in progressive stages of human nonalcoholic fatty liver disease. Drug Metab. Dispos. 2010, 38, 2293–2301. [CrossRef] [PubMed]
70. Fuchs, M.; Sanyal, A.J. Lipotoxicity in NASH. J. Hepatol. 2012, 56, 291–293. [CrossRef] [PubMed]
71. Chakrabarti, A.; Chen, A.W.; Varner, J.D. A review of the mammalian unfolded protein response. Biotechnol. Bioeng. 2011, 108, 2777–2793. [CrossRef] [PubMed]
72. Cazanave, S.C.; Elmi, N.A.; Akazawa, Y.; Bronk, S.F.; Mott, J.L.; Gores, G.J. CHOP and AP-1 cooperatively mediate PUMA expression during lipoapoptosis. Am. J. Physiol. Gastrointest. Liver Physiol. 2010, 299, G236–G243. [CrossRef] [PubMed]
73. Takeda, K.; Akira, S. Toll-like receptors in innate immunity. Int. Immunol. 2005, 17, 1–14. [CrossRef] [PubMed]
74. Deguine, J.; Barton, G.M. MyD88: A central player in innate immune signaling. F1000Prime Rep. 2014, 6, 97. [CrossRef] [PubMed]
75. Werneburg, N.W.; Guicciardi, M.E.; Bronk, S.F.; Gores, G.J. Tumor necrosis factor-alpha-associated lysosomal permeabilization is cathepsin B dependent. Am. J. Physiol. Gastrointest. Liver Physiol. 2002, 283, G947–G956. [CrossRef] [PubMed]
76. Barreyro, F.J.; Kobayashi, S.; Bronk, S.F.; Werneburg, N.W.; Malhi, H.; Gores, G.J. Transcriptional regulation of Bim by FoxO3A mediates hepatocyte lipoapoptosis. J. Biol. Chem. 2007, 282, 27141–27154. [CrossRef] [PubMed]
77. Ponziani, F.R.; Pecere, S.; Gasbarrini, A.; Ojetti, V. Physiology and pathophysiology of liver lipid metabolism. Expert Rev. Gastroenterol. Hepatol. 2015, 9, 1055–1067. [CrossRef] [PubMed]
78. Neish, A.S. Microbes in gastrointestinal health and disease. Gastroenterology 2009, 136, 65–80. [CrossRef] [PubMed]
79. Spencer, M.D.; Hamp, T.J.; Reid, R.W.; Fischer, L.M.; Zeisel, S.H.; Fodor, A.A. Association between composition of the human gastrointestinal microbiome and development of fatty liver with choline deficiency. Gastroenterology 2011, 140, 976–986. [CrossRef] [PubMed]
80. Li, L.; Lu, D.Z.; Li, Y.M.; Zhang, X.Q.; Zhou, X.X.; Jin, X. Proteomic analysis of liver mitochondria from rats with nonalcoholic steatohepatitis. World J. Gastroenterol. 2014, 20, 4778–4786. [CrossRef] [PubMed]
81. Li, Z.Z.; Berk, M.; McIntyre, T.M.; Feldstein, A.E. Hepatic lipid partitioning and liver damage in nonalcoholic fatty liver disease: Role of stearoyl-CoA desaturase. J. Biol. Chem. 2009, 284, 5637–5644. [CrossRef] [PubMed]
82. Akazawa, Y.; Cazanave, S.; Mott, J.L.; Elmi, N.; Bronk, S.F.; Kohno, S.; Charlton, M.R.; Gores, G.J. Palmitoleate attenuates palmitate-induced Bim and PUMA up-regulation and hepatocyte lipoapoptosis. J. Hepatol. 2010, 52, 586–593. [CrossRef] [PubMed]
83. Pawlik, D.; Lauterbach, R.; Walczak, M.; Hurkała, J.; Sherman, M.P. Fish-oil fat emulsion supplementation reduces the risk of retinopathy in very low birth weight infants: A prospective, randomized study. JPEN J. Parenter. Enter. Nutr. 2014, 38, 711–716. [CrossRef] [PubMed]
84. Méndez-Sánchez, N.; González, V.; Aguayo, P.; Sánchez, J.M.; Tanimoto, M.A.; Elizondo, J.; Uribe, M. Fish oil (n-3) polyunsaturated fatty acids beneficially affect biliary cholesterol nucleation time in obese women losing weight. J. Nutr. 2001, 131, 2300–2303. [CrossRef] [PubMed]
85. Monteiro, J.; Leslie, M.; Moghadasian, M.H.; Arendt, B.M.; Allard, J.P.; Ma, D.W. The role of n − 6 and n − 3 polyunsaturated fatty acids in the manifestation of the metabolic syndrome in cardiovascular disease and non-alcoholic fatty liver disease. Food Funct. 2014, 5, 426–435. [CrossRef] [PubMed]
86. He, X.-X.; Wu, X.-L.; Chen, R.-P.; Chen, C.; Liu, X.-G.; Wu, B.-J.; Huang, Z.-M. Effectiveness of Omega-3 Polyunsaturated Fatty Acids in Non-Alcoholic Fatty Liver Disease: A Meta-Analysis of Randomized Controlled Trials. PLoS ONE 2016, 11, E0162368. [CrossRef] [PubMed]
87. El-Badry, A.M.; Graf, R.; Clavien, P.A. Omega 3–omega 6: What is right for the liver? J. Hepatol. 2007, 47, 718–725. [CrossRef] [PubMed]
88. Puri, P.; Baillie, R.A.; Wiest, M.M.; Mirshahi, F.; Choudhury, J.; Cheung, O.; Sargeant, C.; Contos, M.J.; Sanyal, A.J. A lipidomic analysis of nonalcoholic fatty liver disease. Hepatology 2007, 46, 1081–1090. [CrossRef] [PubMed]
89. Videla, L.A.; Rodrigo, R.; Araya, J.; Poniachik, J. Oxidative stress and depletion of hepatic long-chain polyunsaturated fatty acids may contribute to nonalcoholic fatty liver disease. Free Radic. Biol. Med. 2004, 37, 1499–1507. [CrossRef] [PubMed]
90. Belfort, R.; Mandarino, L.; Kashyap, S.; Wirfel, K.; Pratipanawatr, T.; Berria, R.; Defronzo, R.A.; Cusi, K. Dose-response effect of elevated plasma free fatty acid on insulin signaling. Diabetes 2005, 54, 1640–1648. [CrossRef] [PubMed]
91. Samuel, V.T.; Petersen, K.F.; Shulman, G.I. Lipid-induced insulin resistance: Unravelling the mechanism. Lancet 2010, 375, 2267–2277. [CrossRef]
92. Lomonaco, R.; Ortiz-Lopez, C.; Orsak, B.; Webb, A.; Hardies, J.; Darland, C.; Finch, J.; Gastaldelli, A.; Harrison, S.; Tio, F.; et al. Effect of adipose tissue insulin resistance on metabolic parameters and liver histology in obese patients with nonalcoholic fatty liver disease. Hepatology 2012, 55, 1389–1397. [CrossRef] [PubMed]
93. Paolisso, G.; Tataranni, P.A.; Foley, J.E.; Bogardus, C.; Howard, B.V.; Ravussin, E. A high concentration of fasting plasma non-esterified fatty acids is a risk factor for the development of NIDDM. Diabetologia 1995, 38, 1213–1217. [CrossRef] [PubMed]
94. Charles, M.A.; Eschwège, E.; Thibult, N.; Claude, J.R.; Warnet, J.M.; Rosselin, G.E.; Girard, J.; Balkau, B. The role of non-esterified fatty acids in the deterioration of glucose tolerance in Caucasian subjects: Results of the Paris Prospective Study. Diabetologia 1997, 40, 1101–1106. [CrossRef] [PubMed]
95. Beymer, C.; Kowdley, K.V.; Larson, A.; Edmonson, P.; Dellinger, E.P.; Flum, D.R. Prevalence and predictors of asymptomatic liver disease in patients undergoing gastric bypass surgery. Arch. Surg. 2003, 138, 1240–1244. [CrossRef] [PubMed]
96. Ekstedt, M.; Franzén, L.E.; Mathiesen, U.L.; Thorelius, L.; Holmqvist, M.; Bodemar, G.; Kechagias, S. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006, 44, 865–873. [CrossRef] [PubMed]
97. Porepa, L.; Ray, J.G.; Sanchez-Romeu, P.; Booth, G.L. Newly diagnosed diabetes mellitus as a risk factor for serious liver disease. CMAJ 2010, 182, E526–E531. [CrossRef] [PubMed]
98. Musso, G.; Gambino, R.; Cassader, M.; Pagano, G. Meta-analysis: Natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann. Med. 2011, 43, 617–649. [CrossRef] [PubMed]
99. Neuschwander-Tetri, B.A.; Clark, J.M.; Bass, N.M.; Van Natta, M.L.; Unalp-Arida, A.; Tonascia, J.; Zein, C.O.; Brunt, E.M.; Kleiner, D.E.; McCullough, A.J.; et al. NASH Clinical Research Network. Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease. Hepatology 2010, 52, 913–924. [CrossRef] [PubMed]
100. Unger, R.H.; Clark, G.O.; Scherer, P.E.; Orci, L. Lipid homeostasis, lipotoxicity and the metabolic syndrome. Biochim. Biophys. Acta 2010, 1801, 209–214. [CrossRef] [PubMed]
101. Caldwell, S.; Argo, C. The natural history of non-alcoholic fatty liver disease. Dig. Dis. 2010, 28, 162–168. [CrossRef] [PubMed]
102. Mathew, M.; Tay, E.; Cusi, K. Elevated plasma free fatty acids increase cardiovascular risk by inducing plasma biomarkers of endothelial activation, myeloperoxidase and PAI-1 in healthy subjects. Cardiovasc. Diabetol. 2010, 9, 9. [CrossRef] [PubMed]
103. McGavock, J.M.; Lingvay, I.; Zib, I.; Tillery, T.; Salas, N.; Unger, R.; Levine, B.D.; Raskin, P.; Victor, R.G.; Szczepaniak, L.S. Cardiac steatosis in diabetes mellitus: A 1H-magnetic resonance spectroscopy study. Circulation 2007, 116, 1170–1175. [CrossRef] [PubMed]
104. Kankaanpää, M.; Lehto, H.R.; Pärkkä, J.P.; Komu, M.; Viljanen, A.; Ferrannini, E.; Knuuti, J.; Nuutila, P.; Parkkola, R.; Iozzo, P. Myocardial triglyceride content and epicardial fat mass in human obesity: Relationship to left ventricular function and serum free fatty acid levels. J. Clin. Endocrinol. Metab. 2006, 91, 4689–4695. [CrossRef] [PubMed]
105. Rijzewijk, L.J.; Jonker, J.T.; van der Meer, R.W.; Lubberink, M.; de Jong, H.W.; Romijn, J.A.; Bax, J.J.; de Roos, A.; Heine, R.J.; Twisk, J.W.; et al. Effects of hepatic triglyceride content on myocardial metabolism in type 2 diabetes. J. Am. Coll. Cardiol. 2010, 56, 225–233. [CrossRef] [PubMed]
106. Federico, A.; Dallio, M.; Masarone, M.; Persico, M.; Loguercio, C. The epidemiology of non-alcoholic fatty liver disease and its connection with cardiovascular disease: Role of endothelial dysfunction. Eur. Rev. Med. Pharmacol. Sci. 2016, 20, 4731–4741. [PubMed]
107. Neeland, I.J.; Poirier, P.; Després, J.P. Cardiovascular and metabolic heterogeneity of obesity: Clinical challenges and implications for management. Circulation 2018, 137, 1391–1406. [CrossRef] [PubMed]
108. Schindhelm, R.K.; Heine, R.J.; Diamant, M. Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care 2007, 30, e94. [CrossRef] [PubMed]
109. Ong, J.P.; Pitts, A.; Younossi, Z.M. Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease. J. Hepatol. 2008, 49, 608–612. [CrossRef] [PubMed]
110. Rolf Teschke, R.; Wolff, A.; Eickhoff, A.; Danan, G. Is obesity rather than the dietary supplements used for weight reduction the cause of liver injury? J. Gastroenterol. Hepatol. 2018. In press. [CrossRef]
111. Poirier, P.; Giles, T.D.; Bray, G.A.; Hong, Y.; Stern, J.S.; Pi-Sunyer, F.X.; Eckel, R.H. American Heart Association Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. Obesity and cardiovascular disease: Pathophysiology, evaluation, and effect of weight loss: An update of the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease from the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation 2006, 113, 898–918. [CrossRef] [PubMed]
112. Altamirano-Barrera, A.; Barranco-Fragoso, B.; Méndez-Sánchez, N. Management strategies for liver fibrosis. Ann. Hepatol. 2017, 16, 48–56. [CrossRef] [PubMed]
113. Zelber-Sagi, S.; Ratziu, V.; Oren, R. Nutrition and physical activity in NAFLD: An overview of the epidemiological evidence. World J. Gastroenterol. 2011, 17, 3377–3389. [CrossRef] [PubMed]
114. Romero-Gómez, M.; Zelber-Sagi, S.; Trenell, M. Treatment of NAFLD with diet, physical activity and exercise. J. Hepatol. 2017, 67, 829–846. [CrossRef] [PubMed]
115. Van der Heijden, G.J.; Wang, Z.J.; Chu, Z.D.; Sauer, P.J.; Haymond, M.W.; Rodriguez, L.M.; Sunehag, A.L. A 12-week aerobic exercise program reduces hepatic fat accumulation and insulin resistance in obese, Hispanic adolescents. Obesity (Silver Spring) 2010, 18, 384–390. [CrossRef] [PubMed]
116. Almeda-Valdes, P.; Herrera-Mercadillo, R.J.; Aguilar-Salinas, C.A.; Uribe, M.; Méndez-Sánchez, N. The role of diet in patients with metabolic syndrome. Curr. Med. Chem. 2017. [CrossRef] [PubMed]
117. Konerman, M.A.; Jones, J.C.; Harrison, S.A. Pharmacotherapy for NASH: Current and emerging. J. Hepatol. 2018, 68, 362–375. [CrossRef] [PubMed]
118. Sumida, Y.; Yoneda, M. Current and future pharmacological therapies for NAFLD/NASH. J. Gastroenterol. 2018, 53, 362–376. [CrossRef] [PubMed]
119. Sanyal, A.J.; Chalasani, N.; Kowdley, K.V.; McCullough, A.; Diehl, A.M.; Bass, N.M.; Neuschwander-Tetri, B.A.; Lavine, J.E.; Tonascia, J.; Unalp, A.; et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N. Engl. J. Med. 2010, 362, 1675–1685. [CrossRef] [PubMed]
120. Lavine, J.E.; Schwimmer, J.B.; Van Natta, M.L.; Molleston, J.P.; Murray, K.F.; Rosenthal, P.; Abrams, S.H.; Scheimann, A.O.; Sanyal, A.J.; Chalasani, N.; et al. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: The TONIC randomized controlled trial. JAMA 2011, 305, 1659–1668. [CrossRef] [PubMed]
121. Hasegawa, T.; Yoneda, M.; Nakamura, K.; Makino, I.; Terano, A. Plasma transforming growth factor-beta1 level and efficacy of alpha-tocopherol in patients with non-alcoholic steatohepatitis: A pilot study. Aliment. Pharmacol. Ther. 2001, 15, 1667–1672. [CrossRef] [PubMed]
122. Lirussi, F.; Azzalini, L.; Orlando, S.; Orlando, R.; Angelico, F. Antioxidant supplements for non-alcoholic fatty liver disease and/or steatohepatitis. Cochrane Database Syst Rev. 2007, CD004996. [CrossRef] [PubMed]
123. Larion, S.; Khurana, S. Clinical studies investigating the effect of vitamin E therapy in patients with NASH. Clin. Liver Dis. 2018, 11, 16–21. [CrossRef]
124. Chalasani, N.; Younossi, Z.; Lavine, J.E.; Charlton, M.; Cusi, K.; Rinella, M.; Harrison, S.A.; Brunt, E.M.; Sanyal, A.J. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology 2018, 67, 328–357. [CrossRef] [PubMed]
125. Rinella, M.E.; Sanyal, A.J. Management of NAFLD: A stage-based approach. Nat. Rev. Gastroenterol. Hepatol. 2016, 13, 196–205. [CrossRef] [PubMed]
126. Miller, E.R., 3rd; Pastor-Barriuso, R.; Dalal, D.; Riemersma, R.A.; Appel, L.J.; Guallar, E. Meta-analysis: High-dosage vitamin E supplementation may increase all-cause mortality. Ann. Intern. Med. 2005, 142, 37–46. [CrossRef] [PubMed]
127. Lippman, S.M.; Klein, E.A.; Goodman, P.J.; Lucia, M.S.; Thompson, I.M.; Ford, L.G.; Parnes, H.L.; Minasian, L.M.; Gaziano, J.M.; Hartline, J.A.; et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: The Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 2009, 301, 39–51. [CrossRef] [PubMed]
128. Schürks, M.; Glynn, R.J.; Rist, P.M.; Tzourio, C.; Kurth, T. Effects of vitamin E on stroke subtypes: Meta-analysis of randomised controlled trials. BMJ 2010, 341, c5702. [CrossRef] [PubMed]
129. Ratziu, V.; Goodman, Z.; Sanyal, A. Current efforts and trends in the treatment of NASH. J. Hepatol. 2015, 62, S65–S75. [CrossRef] [PubMed]
130. Ahmed, M. Non-alcoholic fatty liver disease in 2015. World J. Hepatol. 2015, 7, 1450–1459. [CrossRef] [PubMed]
131. DeFronzo, R.A.; Tripathy, D.; Schwenke, D.C.; Banerji, M.; Bray, G.A.; Buchanan, T.A.; Clement, S.C.; Henry, R.R.; Hodis, H.N.; Kitabchi, A.E.; et al. Pioglitazone for diabetes prevention in impaired glucose tolerance. N. Engl. J. Med. 2011, 364, 1104–1115. [CrossRef] [PubMed]
132. Bril, F.; Kalavalapalli, S.; Clark, V.C.; Lomonaco, R.; Soldevila-Pico, C.; Liu, I.C.; Orsak, B.; Tio, F.; Cusi, K. Response to pioglitazone in patients with nonalcoholic steatohepatitis with vs. without type 2 diabetes. Clin. Gastroenterol. Hepatol. 2018, 16, 558–566. [CrossRef] [PubMed]
133. Cusi, K.; Orsak, B.; Bril, F.; Lomonaco, R.; Hecht, J.; Ortiz-Lopez, C.; Tio, F.; Hardies, J.; Darland, C.; Musi, N.; et al. Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: A randomized trial. Ann. Intern. Med. 2016, 165, 305–315. [CrossRef] [PubMed]
134. Belfort, R.; Harrison, S.A.; Brown, K.; Darland, C.; Finch, J.; Hardies, J.; Balas, B.; Gastaldelli, A.; Tio, F.; Pulcini, J.; et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N. Engl. J. Med. 2006, 355, 2297–2307. [CrossRef] [PubMed]
135. Aguilar-Olivos, N.E.; Almeda-Valdes, P.; Aguilar-Salinas, C.A.; Uribe, M.; Méndez-Sánchez, N. The role of bariatric surgery in the management of nonalcoholic fatty liver disease and metabolic syndrome. Metabolism 2016, 65, 1196–1207. [CrossRef] [PubMed]
136. Schauer, P.R.; Bhatt, D.L.; Kirwan, J.P.; Wolski, K.; Brethauer, S.A.; Navaneethan, S.D.; Aminian, A.; Pothier, C.E.; Kim, E.S.; Nissen, S.E.; et al. Bariatric surgery versus intensive medical therapy for diabetes—3-year outcomes. N. Engl. J. Med. 2014, 370, 2002–2013. [CrossRef] [PubMed]
137. Weiner, R.A. Surgical treatment of non-alcoholic steatohepatitis and non-alcoholic fatty liver disease. Dig. Dis. 2010, 28, 274–279. [CrossRef] [PubMed]
138. Abu Dayyeh, B.K.; Thompson, C.C. Obesity and bariatrics for the endoscopist: New techniques. Ther. Adv. Gastroenterol. 2011, 4, 433–442. [CrossRef] [PubMed]
139. Choi, H.S.; Chun, H.J. Recent trends in endoscopic bariatric therapies. Clin. Endosc. 2017, 50, 11–16. [CrossRef] [PubMed]
140. Lee, Y.M.; Low, H.C.; Lim, L.G.; Dan, Y.Y.; Aung, M.O.; Cheng, C.L.; Wee, A.; Lim, S.G.; Ho, K.Y. Intragastric balloon significantly improves non-alcoholic fatty liver disease activity score in obese patients with nonalcoholic steatohepatitis: A pilot study. Gastrointest. Endosc. 2012, 76, 756–760. [CrossRef] [PubMed]
141. Hossain, N.; Kanwar, P.; Mohanty, S.R. A comprehensive updated review of pharmaceutical and nonpharmaceutical treatment for NAFLD. Gastroenterol. Res. Pract. 2016, 2016, 7109270. [CrossRef] [PubMed]
142. Abenavoli, L.; Capasso, R.; Milic, N.; Capasso, F. Milk thistle in liver diseases: Past, present, future. Phytother. Res. 2010, 24, 1423–1432. [CrossRef] [PubMed]
143. Gazák, R.; Walterová, D.; Kren, V. Silybin and silymarin–new and emerging applications in medicine. Curr. Med. Chem. 2007, 14, 315–338. [CrossRef] [PubMed]
144. Saller, R.; Meier, R.; Brignoli, R. The use of silymarin in the treatment of liver diseases. Drugs 2001, 61, 2035–2063. [CrossRef] [PubMed]
145. Velussi, M.; Cernigoi, A.M.; De Monte, A.; Dapas, F.; Caffau, C.; Zilli, M. Long-term (12 months) treatment with an anti-oxidant drug (silymarin) is effective on hyperinsulinemia, exogenous insulin need and malondialdehyde levels in cirrhotic diabetic patients. J. Hepatol. 1997, 26, 871–879. [CrossRef]
146. Hajiaghamohammadi, A.A.; Ziaee, A.; Samimi, R. The efficacy of licorice root extract in decreasing transaminase activities in non-alcoholic fatty liver disease: A randomized controlled clinical trial. Phytother. Res. 2012, 26, 1381–1384. [CrossRef] [PubMed]
147. Loguercio, C.; Andreone, P.; Brisc, C.; Brisc, M.C.; Bugianesi, E.; Chiaramonte, M.; Cursaro, C.; Danila, M.; de Sio, I.; Floreani, A.; et al. Silybin combined with phosphatidylcholine and vitamin E in patients with nonalcoholic fatty liver disease: A randomized controlled trial. Free Radic. Biol. Med. 2012, 52, 1658–1665. [CrossRef] [PubMed]
148. Serviddio, G.; Bellanti, F.; Giudetti, A.M.; Gnoni, G.V.; Petrella, A.; Tamborra, R.; Romano, A.D.; Rollo, T.; Vendemiale, G.; Altomare, E. A silybin-phospholipid complex prevents mitochondrial dysfunction in a rodent model of nonalcoholic steatohepatitis. J. Pharmacol. Exp. Ther. 2010, 332, 922–932. [CrossRef] [PubMed]
149. Saller, R.; Brignoli, R.; Melzer, J.; Meier, R. An updated systematic review with meta-analysis for the clinical evidence of silymarin. Forsch. Komplementmed. 2008, 15, 9–20. [CrossRef] [PubMed]
150. Hung, C.K.; Bodenheimer, H.C., Jr. Current Treatment of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis. Clin. Liver Dis. 2018, 22, 175–187. [CrossRef] [PubMed]
151. Shen, H.; Rodriguez, A.C.; Shiani, A.; Lipka, S.; Shahzad, G.; Kumar, A.; Mustacchia, P. Association between caffeine consumption and nonalcoholic fatty liver disease: A systemic review and meta-analysis. Ther. Adv. Gastroenterol. 2016, 9, 113–120. [CrossRef] [PubMed]
152. Zelber-Sagi, S.; Salomone, F.; Webb, M.; Lotan, R.; Yeshua, H.; Halpern, Z.; Santo, E.; Oren, R.; Shibolet, O. Coffee consumption and nonalcoholic fatty liver onset: A prospective study in the general population. Transl. Res. 2015, 165, 428–436. [CrossRef] [PubMed]
153. Molloy, J.W.; Calcagno, C.J.; Williams, C.D.; Jones, F.J.; Torres, D.M.; Harrison, S.A. Association of coffee and caffeine consumption with fatty liver disease, nonalcoholic steatohepatitis, and degree of hepatic fibrosis. Hepatology 2012, 55, 429–436. [CrossRef] [PubMed]
154. Birerdinc, A.; Stepanova, M.; Pawloski, L.; Younossi, Z.M. Caffeine is protective in patients with non-alcoholic fatty liver disease. Aliment. Pharmacol. Ther. 2012, 35, 76–82. [CrossRef] [PubMed]
155. Cadden, I.S.; Partovi, N.; Yoshida, E.M. Review article: Possible beneficial effects of coffee on liver disease and function. Aliment. Pharmacol. Ther. 2007, 26, 1–8. [CrossRef] [PubMed]
156. Vitaglione, P.; Morisco, F.; Mazzone, G.; Amoruso, D.C.; Ribecco, M.T.; Romano, A.; Fogliano, V.; Caporaso, N.; D’argenio, G. Coffee reduces liver damage in a rat model of steatohepatitis: The underlying mechanisms and the role of polyphenols and melanoidins. Hepatology 2010, 52, 1652–1661. [CrossRef] [PubMed]
157. Mizrahi, M.; Shabat, Y.; Ben Ya’acov, A.; Lalazar, G.; Adar, T.; Wong, V.; Muller, B.; Rawlin, G.; Ilan, Y. Alleviation of insulin resistance and liver damage by oral administration of Imm124-E is mediated by increased Tregs and associated with increased serum GLP-1 and adiponectin: Results of a phase I/II clinical trial in NASH. J. Inflamm. Res. 2012, 5, 141–150. [CrossRef] [PubMed]
158. Zelber-Sagi, S.; Kessler, A.; Brazowsky, E.; Webb, M.; Lurie, Y.; Santo, M.; Leshno, M.; Blendis, L.; Halpern, Z.; Oren, R. A double-blind randomized placebo-controlled trial of orlistat for the treatment of nonalcoholic fatty liver disease. Clin. Gastroenterol. Hepatol. 2006, 4, 639–644. [CrossRef] [PubMed]
159. Geier, A.; Rau, M. Emerging therapies for NASH—The future is now. Expert Rev. Clin. Pharmacol. 2017, 10, 467–469. [CrossRef] [PubMed]
160. Cruz-Ramón, V.; Chinchilla-López, P.; Ramírez-Pérez, O.; Méndez-Sánchez, N. Bile Acids in Nonalcoholic Fatty Liver Disease: New Concepts and therapeutic advances. Ann. Hepatol. 2017, 16 (Suppl. 1), s58–s67. [CrossRef] [PubMed]
161. Oseini, A.M.; Sanyal, A.J. Therapies in non-alcoholic steatohepatitis (NASH). Liver Int. 2017, 37 (Suppl. 1), 97–103. [CrossRef] [PubMed]